瑞舒伐他汀治疗高血脂并高尿酸血症患者的疗效研究

Therapeutic effect of rosuvastatin on patients with hyperlipidemia complicated hyperuricemia

目的:评价瑞舒伐他汀对高血脂并高尿酸血症患者的疗效和安全性。方法:选择我院住院治疗的高血脂合并高尿酸血症患者88例,随机均分为瑞舒伐他汀组(10mg/d)和阿托伐他汀组(20mg/d),治疗8周。观察两组治疗前后血脂和血清尿酸(SUA)水平的变化。结果:与治疗前相比,两组患者治疗8周后血脂(除高密度脂蛋白-胆固醇)和SUA水平均明显降低(P均<0.01);与阿托伐他汀组比较,瑞舒伐他汀组治疗后总胆固醇[(4.87±0.47)mmol/L比(4.48±0.53)mmol/L]水平降低更显著(P=0.04),两组间治疗后SUA水平无显著差异(P>0.05)。两组均未出现比较严重的副作用。结论:瑞舒伐他汀在降低高血脂患者血脂水平同时亦可降低血清尿酸水平,且具有良好的安全性和耐受性。

Objective： To evaluate therapeutic effect and safety of rosuvastatin on patients with hyperlipidemia com- plicated hyperuricemia. Methods： A total of 88 patients with hyperlipidemia complicated hyperuricemia, who were hospitalized in our hospital, were selected, randomly and equally divided into rosuvastatin group （10 mg/d） and atorvastatin group （20mg/d）, both groups were treated for eight weeks. Changes of levels of blood lipids and serum uric acid （SUA） were observed and compared between two groups before and after treatment. Results： Compared with before treatment, after eight-week treatment, there were significant reductions in levels of blood lipids （ex- cept high density lipoprotein cholesterol） and SUA in both groups, P^0.01 all; compared with atorvastatin group after treatment, there were significant reductions in levels of total cholesterol [ （4.87±0.47） mmol/L vs. （4. 48 ±0.53） mmol/L] in rosuvastatin group （P = 0.04）, and there was no significant difference in SUA level between two groups, P〈0.05. There were all no more serious side effects in both groups. Conclusion： While reducing blood lipid levels, rosuvastatin can also reduce serum uric acid level in patients with hyperlipidemia, and it possesses good safety and tolerance.